Dillon & Associates Inc. Purchases 1,271 Shares of Novo Nordisk A/S (NYSE:NVO)

Dillon & Associates Inc. raised its position in Novo Nordisk A/S (NYSE:NVO) by 0.5% during the third quarter, Holdings Channel reports. The firm owned 283,417 shares of the company’s stock after purchasing an additional 1,271 shares during the period. Novo Nordisk A/S comprises 4.7% of Dillon & Associates Inc.’s portfolio, making the stock its 3rd largest holding. Dillon & Associates Inc.’s holdings in Novo Nordisk A/S were worth $33,727,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of NVO. GQG Partners LLC lifted its position in shares of Novo Nordisk A/S by 654.6% during the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock valued at $466,485,000 after acquiring an additional 3,151,584 shares during the period. International Assets Investment Management LLC grew its stake in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC grew its stake in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Acadian Asset Management LLC grew its position in Novo Nordisk A/S by 1,300.8% during the first quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock valued at $159,703,000 after buying an additional 1,155,313 shares during the period. Finally, Mediolanum International Funds Ltd bought a new position in Novo Nordisk A/S during the third quarter valued at about $98,765,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of a number of recent analyst reports. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $107.05 on Wednesday. The business has a 50-day simple moving average of $120.82 and a two-hundred day simple moving average of $130.22. The firm has a market cap of $480.39 billion, a price-to-earnings ratio of 34.64, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a fifty-two week low of $94.73 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.